Singapore markets close in 7 hours 42 minutes

Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.2400-0.0600 (-2.61%)
At close: 04:00PM EST
2.2300 -0.01 (-0.45%)
After hours: 07:38PM EST

Corvus Pharmaceuticals, Inc.

863 Mitten Road
Suite 102
Burlingame, CA 94010
United States
650 900 4520
https://www.corvuspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees29

Key executives

NameTitlePayExercisedYear born
Dr. Richard A. Miller M.D.Co-Founder, President, CEO & Chairman of the Board306kN/A1951
Dr. Peter A. Thompson FACP, M.D.Co-Founder & Independent Director47kN/A1960
Mr. Leiv LeaChief Financial Officer388.73kN/A1954
Dr. William Benton Jones Ph.D.Senior Vice President of Pharmaceutical Development346.42kN/A1966
Dr. James T. Rosenbaum M.D.Senior Vice President of ResearchN/AN/AN/A
Mr. Jeffrey S. ArcaraChief Business OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Corporate governance

Corvus Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.